Adopted as a "Model Project for Promoting Decarbonization throughout the Value Chain" by the Ministry of the Environment
～12 companies participate in the project to establish common rules for calculating CO2 emissions in the pharmaceutical industry
July 22, 2025
Japan Pharmaceutical Manufacturers Association
We are pleased to announce that the Carbon Neutral Group of the Environmental Issue Committee of the Japan Pharmaceutical Manufacturers Association (JPMA) has applied for the "Model Project for Promotion of Decarbonization throughout the Value Chain (Industry Organization)" for fiscal 2025, which was publicly solicited by the Ministry of the Environment of Japan, and that the application has been informally accepted.
The following 12 JPMA member companies will participate in this project.
Astellas Pharma Inc., AstraZeneca K.K., Eisai Co., Kissei Pharmaceutical Industries, Ltd., Sanofi K.K., Santen Co., Ltd., Shionogi & Co.
The Japan Pharmaceutical Manufacturers Association (JPMA), in cooperation with its member companies, is promoting efforts to achieve carbon neutrality throughout the pharmaceutical industry.
This project aims to reduce emissions throughout the value chain on an industry-wide basis, and supports efforts to establish industry-wide Scope 3 calculation and primary data acquisition rules and guidelines for engagement policies.
This initiative will contribute to the realization of "Trust: Ensure ethics and transparency and become an industry trusted by society", one of the priority areas in JPMA's Vision for 2035, which was announced in February 2025. The knowledge gained through this project will be shared widely to contribute to solving environmental issues such as climate change, which has a serious impact on human health. By doing so, we aim to realize a sustainable society that supports a stable supply of pharmaceuticals.